Copyright Reports & Markets. All rights reserved.

Global LNP-mRNA Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of LNP-mRNA Therapy by Type
    • 1.3.1 Overview: Global LNP-mRNA Therapy Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global LNP-mRNA Therapy Consumption Value Market Share by Type in 2025
    • 1.3.3 Passive Targeting
    • 1.3.4 Active Targeting
  • 1.4 Classification of LNP-mRNA Therapy by Treatment Direction
    • 1.4.1 Overview: Global LNP-mRNA Therapy Market Size by Treatment Direction: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global LNP-mRNA Therapy Consumption Value Market Share by Treatment Direction in 2025
    • 1.4.3 Vaccines
    • 1.4.4 Cancer Immunotherapy
    • 1.4.5 Genetic Disease Therapy
    • 1.4.6 Others
  • 1.5 Classification of LNP-mRNA Therapy by Mechanisms of Action
    • 1.5.1 Overview: Global LNP-mRNA Therapy Market Size by Mechanisms of Action: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global LNP-mRNA Therapy Consumption Value Market Share by Mechanisms of Action in 2025
    • 1.5.3 Protein Replacement Therapy
    • 1.5.4 Immune Activation Therapy
    • 1.5.5 Gene Regulation Therapy
  • 1.6 Global LNP-mRNA Therapy Market by Application
    • 1.6.1 Overview: Global LNP-mRNA Therapy Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Clinic
    • 1.6.4 Others
  • 1.7 Global LNP-mRNA Therapy Market Size & Forecast
  • 1.8 Global LNP-mRNA Therapy Market Size and Forecast by Region
    • 1.8.1 Global LNP-mRNA Therapy Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global LNP-mRNA Therapy Market Size by Region, (2021-2032)
    • 1.8.3 North America LNP-mRNA Therapy Market Size and Prospect (2021-2032)
    • 1.8.4 Europe LNP-mRNA Therapy Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific LNP-mRNA Therapy Market Size and Prospect (2021-2032)
    • 1.8.6 South America LNP-mRNA Therapy Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa LNP-mRNA Therapy Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Genevant Sciences
    • 2.1.1 Genevant Sciences Details
    • 2.1.2 Genevant Sciences Major Business
    • 2.1.3 Genevant Sciences LNP-mRNA Therapy Product and Solutions
    • 2.1.4 Genevant Sciences LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Genevant Sciences Recent Developments and Future Plans
  • 2.2 Moderna
    • 2.2.1 Moderna Details
    • 2.2.2 Moderna Major Business
    • 2.2.3 Moderna LNP-mRNA Therapy Product and Solutions
    • 2.2.4 Moderna LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Moderna Recent Developments and Future Plans
  • 2.3 BioNTech
    • 2.3.1 BioNTech Details
    • 2.3.2 BioNTech Major Business
    • 2.3.3 BioNTech LNP-mRNA Therapy Product and Solutions
    • 2.3.4 BioNTech LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 BioNTech Recent Developments and Future Plans
  • 2.4 Pfizer
    • 2.4.1 Pfizer Details
    • 2.4.2 Pfizer Major Business
    • 2.4.3 Pfizer LNP-mRNA Therapy Product and Solutions
    • 2.4.4 Pfizer LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Pfizer Recent Developments and Future Plans
  • 2.5 NanoVation Therapeutics
    • 2.5.1 NanoVation Therapeutics Details
    • 2.5.2 NanoVation Therapeutics Major Business
    • 2.5.3 NanoVation Therapeutics LNP-mRNA Therapy Product and Solutions
    • 2.5.4 NanoVation Therapeutics LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 NanoVation Therapeutics Recent Developments and Future Plans
  • 2.6 CureVac
    • 2.6.1 CureVac Details
    • 2.6.2 CureVac Major Business
    • 2.6.3 CureVac LNP-mRNA Therapy Product and Solutions
    • 2.6.4 CureVac LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 CureVac Recent Developments and Future Plans
  • 2.7 Sanofi
    • 2.7.1 Sanofi Details
    • 2.7.2 Sanofi Major Business
    • 2.7.3 Sanofi LNP-mRNA Therapy Product and Solutions
    • 2.7.4 Sanofi LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sanofi Recent Developments and Future Plans
  • 2.8 Promab
    • 2.8.1 Promab Details
    • 2.8.2 Promab Major Business
    • 2.8.3 Promab LNP-mRNA Therapy Product and Solutions
    • 2.8.4 Promab LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Promab Recent Developments and Future Plans
  • 2.9 Grand Pharm
    • 2.9.1 Grand Pharm Details
    • 2.9.2 Grand Pharm Major Business
    • 2.9.3 Grand Pharm LNP-mRNA Therapy Product and Solutions
    • 2.9.4 Grand Pharm LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Grand Pharm Recent Developments and Future Plans
  • 2.10 Arcturus Therapeutics
    • 2.10.1 Arcturus Therapeutics Details
    • 2.10.2 Arcturus Therapeutics Major Business
    • 2.10.3 Arcturus Therapeutics LNP-mRNA Therapy Product and Solutions
    • 2.10.4 Arcturus Therapeutics LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Arcturus Therapeutics Recent Developments and Future Plans
  • 2.11 Synplogen
    • 2.11.1 Synplogen Details
    • 2.11.2 Synplogen Major Business
    • 2.11.3 Synplogen LNP-mRNA Therapy Product and Solutions
    • 2.11.4 Synplogen LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Synplogen Recent Developments and Future Plans
  • 2.12 CSPC
    • 2.12.1 CSPC Details
    • 2.12.2 CSPC Major Business
    • 2.12.3 CSPC LNP-mRNA Therapy Product and Solutions
    • 2.12.4 CSPC LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 CSPC Recent Developments and Future Plans
  • 2.13 Beijing JenKem Technology
    • 2.13.1 Beijing JenKem Technology Details
    • 2.13.2 Beijing JenKem Technology Major Business
    • 2.13.3 Beijing JenKem Technology LNP-mRNA Therapy Product and Solutions
    • 2.13.4 Beijing JenKem Technology LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Beijing JenKem Technology Recent Developments and Future Plans
  • 2.14 Starna Therapeutics
    • 2.14.1 Starna Therapeutics Details
    • 2.14.2 Starna Therapeutics Major Business
    • 2.14.3 Starna Therapeutics LNP-mRNA Therapy Product and Solutions
    • 2.14.4 Starna Therapeutics LNP-mRNA Therapy Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Starna Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global LNP-mRNA Therapy Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of LNP-mRNA Therapy by Company Revenue
    • 3.2.2 Top 3 LNP-mRNA Therapy Players Market Share in 2025
    • 3.2.3 Top 6 LNP-mRNA Therapy Players Market Share in 2025
  • 3.3 LNP-mRNA Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 LNP-mRNA Therapy Market: Region Footprint
    • 3.3.2 LNP-mRNA Therapy Market: Company Product Type Footprint
    • 3.3.3 LNP-mRNA Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global LNP-mRNA Therapy Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global LNP-mRNA Therapy Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global LNP-mRNA Therapy Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global LNP-mRNA Therapy Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America LNP-mRNA Therapy Consumption Value by Type (2021-2032)
  • 6.2 North America LNP-mRNA Therapy Market Size by Application (2021-2032)
  • 6.3 North America LNP-mRNA Therapy Market Size by Country
    • 6.3.1 North America LNP-mRNA Therapy Consumption Value by Country (2021-2032)
    • 6.3.2 United States LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 6.3.3 Canada LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico LNP-mRNA Therapy Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe LNP-mRNA Therapy Consumption Value by Type (2021-2032)
  • 7.2 Europe LNP-mRNA Therapy Consumption Value by Application (2021-2032)
  • 7.3 Europe LNP-mRNA Therapy Market Size by Country
    • 7.3.1 Europe LNP-mRNA Therapy Consumption Value by Country (2021-2032)
    • 7.3.2 Germany LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 7.3.3 France LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 7.3.5 Russia LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 7.3.6 Italy LNP-mRNA Therapy Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific LNP-mRNA Therapy Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific LNP-mRNA Therapy Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific LNP-mRNA Therapy Market Size by Region
    • 8.3.1 Asia-Pacific LNP-mRNA Therapy Consumption Value by Region (2021-2032)
    • 8.3.2 China LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 8.3.3 Japan LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 8.3.5 India LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 8.3.7 Australia LNP-mRNA Therapy Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America LNP-mRNA Therapy Consumption Value by Type (2021-2032)
  • 9.2 South America LNP-mRNA Therapy Consumption Value by Application (2021-2032)
  • 9.3 South America LNP-mRNA Therapy Market Size by Country
    • 9.3.1 South America LNP-mRNA Therapy Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina LNP-mRNA Therapy Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa LNP-mRNA Therapy Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa LNP-mRNA Therapy Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa LNP-mRNA Therapy Market Size by Country
    • 10.3.1 Middle East & Africa LNP-mRNA Therapy Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia LNP-mRNA Therapy Market Size and Forecast (2021-2032)
    • 10.3.4 UAE LNP-mRNA Therapy Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 LNP-mRNA Therapy Market Drivers
  • 11.2 LNP-mRNA Therapy Market Restraints
  • 11.3 LNP-mRNA Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 LNP-mRNA Therapy Industry Chain
  • 12.2 LNP-mRNA Therapy Upstream Analysis
  • 12.3 LNP-mRNA Therapy Midstream Analysis
  • 12.4 LNP-mRNA Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global LNP-mRNA Therapy market size was valued at US$ 569 million in 2025 and is forecast to a readjusted size of US$ 823 million by 2032 with a CAGR of 5.5% during review period.
    LNP-mRNA Therapy represents a cutting-edge biomedical technology that leverages the unique strengths of Lipid Nanoparticles (LNPs) and Messenger RNA (mRNA) to offer novel treatment avenues for various diseases. Serving as carriers, LNPs effectively shield mRNA from enzymatic degradation in the body and deliver it precisely to target cells. mRNA carries the genetic information necessary for synthesizing specific proteins; once inside cells, it directs the cells to produce these proteins, thereby triggering immune responses or repairing damaged tissues. This therapy demonstrates significant potential in treating cancers, genetic disorders, and infectious diseases. Its highly personalized and rapid-response characteristics have made LNP-mRNA Therapy a research focus in the biomedical field. By precisely regulating gene expression, LNP-mRNA Therapy provides patients with unprecedented treatment options, ushering in a new era of precision medicine.
    The LNP-mRNA Therapy market is in a phase of rapid development. Following the successful application of COVID-19 vaccines, global R&D focus has expanded to areas such as cancer immunotherapy, rare genetic diseases, cardiovascular diseases, and regenerative medicine. With the optimization of intelligent delivery systems and the maturation of production processes, the market size is expected to maintain high growth over the next decade, driven by the needs of infectious disease control, large-scale data center-based vaccine production capabilities, investment in new energy medical technologies, and the trend towards precision medicine. Despite challenges such as cost, stability, and regulation, with policy support and capital investment in North America, Europe, and the Asia-Pacific region, LNP-mRNA technology is poised to become a core platform for next-generation biomedicine, driving the upgrading of the global pharmaceutical industry structure.
    This report is a detailed and comprehensive analysis for global LNP-mRNA Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global LNP-mRNA Therapy market size and forecasts, in consumption value ($ Million), 2021-2032
    Global LNP-mRNA Therapy market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global LNP-mRNA Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global LNP-mRNA Therapy market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for LNP-mRNA Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global LNP-mRNA Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genevant Sciences, Moderna, BioNTech, Pfizer, NanoVation Therapeutics, CureVac, Sanofi, Promab, Grand Pharm, Arcturus Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    LNP-mRNA Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Passive Targeting
    Active Targeting
    Market segment by Treatment Direction
    Vaccines
    Cancer Immunotherapy
    Genetic Disease Therapy
    Others
    Market segment by Mechanisms of Action
    Protein Replacement Therapy
    Immune Activation Therapy
    Gene Regulation Therapy
    Market segment by Application
    Hospital
    Clinic
    Others
    Market segment by players, this report covers
    Genevant Sciences
    Moderna
    BioNTech
    Pfizer
    NanoVation Therapeutics
    CureVac
    Sanofi
    Promab
    Grand Pharm
    Arcturus Therapeutics
    Synplogen
    CSPC
    Beijing JenKem Technology
    Starna Therapeutics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe LNP-mRNA Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of LNP-mRNA Therapy, with revenue, gross margin, and global market share of LNP-mRNA Therapy from 2021 to 2026.
    Chapter 3, the LNP-mRNA Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and LNP-mRNA Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of LNP-mRNA Therapy.
    Chapter 13, to describe LNP-mRNA Therapy research findings and conclusion.

    Buy now